FDA advisers support OTC use of Sanofi's nasal spray

07/31/2013 | Reuters · Pharmaceutical Business Review Online

An FDA advisory panel voted 10-6 in favor of allowing Sanofi's Nasacort AQ nasal spray to be sold without a prescription. If approved, the respiratory allergy drug would be the first over-the-counter intranasal corticosteroid available in the U.S.

View Full Article in:

Reuters · Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC